Breaking News on Contract Research, Manufacturing & Clinical Trials

Phase I-II


Download now!Research study

Early Alzheimer’s Disease and patient recruitment - CCBR COMPANY INFORMATION

30-Mar-2015 - The increasing challenges in delivering patient enrolment, treatment and retention in clinical trials exist in all Therapeutic Areas but are particularly acute in Prodromal and early symptomatic Alzheimer’s disease. The traditional model of opening ever increasing numbers of sites across...
Register now!Live Supplier Webinar

The whole blood assay: Detection of broad spectrum of pyrogens & examples of medical device testing - Merck Millipore microbial industry

09-Mar-2015 - Pyrogens in pharmaceuticals, medical devices, biotherapeutics and cosmetics can cause fevers in humans and are potentially life-threatening. Yet standard pyrogen detection methods have drawbacks. The Limulus Amoebocyte Lysate (LAL) test only identifies endotoxins, while the rabbit pyrogen test (RPT) endangers...
Download now!Technical / white paper

Transdermal Delivery Systems - QPS

01-May-2014 - Whereas dermatologic topical formulations (foams, creams, lotions, ointments, gels, etc.) target skin diseases, topical transdermal delivery systems (TDDS) are designed to treat systemic medical conditions or localized joint or muscle conditions, using the skin as the route of drug delivery....
Download now!Application note

Broad spectrum pyrogen detection - EMD Millipore

02-Dec-2014 - The Monocyte-Activation Test (MAT), which was introduced into the European Pharmacopoeia in 2010, detects pyrogens in pharmaceuticals. It covers a much broader range of pyrogens than the LAL Test, which traces only endotoxins. As an alternative to rabbit pyrogen testing...
Download now!Application note

Broad spectrum pyrogen detection according to pharmacopoeia - Merck Millipore microbial industry

01-Dec-2014 - The Monocyte-Activation Test (MAT), which was introduced into the European Pharmacopoeia in 2010, detects pyrogens in pharmaceuticals. It covers a much broader range of pyrogens than the LAL Test, which traces only endotoxins. As an alternative to rabbit pyrogen testing...
Download now!Case study

Mobile ePRO makes a difference: Trigemina’s TI-001 formulation including intranasal oxytocin clinical study - Exco InTouch

18-Nov-2014 - Trigemina is a clinical stage specialty pharmaceutical company that develops non-narcotic, nasally delivered, analgesic drug products including TI-001, a patented application of oxytocin with a novel mode of action, which is currently in a phase II clinical study for high...
Download now!Press release

Veristat and Karyopharm Therapeutics Inc. Agreement - Veristat, LLC

20-Jun-2014 - HOLLISTON, Mass. – June 15, 2014 – Veristat, a full service Contract Research Organization, announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets...
Download now!Clinical study

Learn the risk factors of metabolic syndrome and the role central labs play in aiding its detection - ACM Global Central Laboratory

17-Jun-2014 - Metabolic syndrome, a serious condition impacting adults and children in all genders, races and ethnicities, can lead to fatal outcomes if not detected and treated. The key risk factors of metabolic syndrome were identified approximately 250 years ago. However, there...
Watch now!On-Demand Supplier Webinar

Industry leading titers of protein in E.coli - Fujifilm

26-May-2014 - The development of large scale E. coli expression systems can be rate limiting in process development.  Fujifilm's pAVEway™ system combines innovative vector technology with platform fermentation processes to rapidly delivers industry leading titers.
Download now!Case study

Fast and Flexible – Early Phase Manufacturing - Patheon Inc

05-May-2014 - Early-stage manufacturers of oral solid dosage forms need to be fast and flexible to generate development pathways that can cope with variable API characteristics as well as highly potent molecules. Technology, risk assessment, Quality by Design and scale up are...
Download now!Technical / white paper

The Promise and Challenge of Adaptive Design: Oncology Trials - Medpace

05-May-2014 - Incorporating adaptive design methodologies into clinical trials can reduce costs while maintaining trial integrity.  Learn how these design strategies can improve the effectiveness and efficiency of oncology studies
Download now!Data sheet

Orthotopic Brain Tumor Models Improved with Imaging - Molecular Imaging Inc.

14-Apr-2014 - Know more: enhance in vivo pharmacology with imaging. Recent tumor model development and informative imaging technologies have enabled the efficient and robust use of orthotopic models. These models have proven to be the most clinically relevant and predictive cancer models....
Download now!Technical / white paper

Forecasting strategies to optimize clinical trials - Almac Group

03-Mar-2014 - In a market that is constantly evolving, where rising complexities and costs associated with product development and clinical trial conduct present new clinical supply chain challenges, conventional forecasting methods may not provide an adequate solution.  Add to this the increasing...
Download now!Technical / white paper

Applying a Health- and Science- based Risk Assessment for Multi-Product Biologics manufacturing - Fujifilm

18-Nov-2013 - Over the last 10-15 years, it has become common practice to manufacture biologics intended for clinical trials (Investigational Medicinal Products, or IMPs) in multi-purpose facilities.This flexibility has been a key enabler in ensuring a flow of novel products, frequently targeting...
Download now!Case study

Controlled Release and Bioavailability Enhancement -

28-Oct-2013 - Metrics provides product development that leverages proprietary pharmaceutical technologies in the areas of: •    Customized Controlled Release Drug Delivery •    Bioavailability Enhancement •    Taste Masking (liquid and solid presentations)When applied appropriately, these technologies can deliver therapeutic and convenience benefits to...
Download now!Data sheet

505(b)(2): 10 Years and Running with 300+ Approvals - Camargo

21-Oct-2013 - In 2003, the FDA unleashed the 505(b)(2) pathway. With a record 47 approvals in 2012, the pathway is helping product developers secure up to 7 years of market exclusivity.Visit us at AAPS booth 4304 and read our white paper to learn more.
Watch now!On-Demand Supplier Webinar

New Guidelines for Stabilization of Proteins by Freeze Drying: Formulation and Process Heresy - Baxter

17-Oct-2013 - Over the years a number of informal guidelines or “rules” for the formulation and processing of proteins for freeze-drying have been developed. However, in recent years it has become obvious that some of these rules need modification. In this presentation,...
Download now!Technical / white paper


23-Sep-2013 - To understand why there is so much buzz in the pharmaceutical world for a better HCV treat­ment, as with most things, you have to start with history. This article will highlight the history, why there is a growing need for...
Download now!Technical / white paper

Patient Reminders: Improve Retention & Compliance - Cenduit

02-Sep-2013 - The average cost of a patient lost to follow-up is $5,000.  Read on to learn how to incorporate patient reminders into your protocol to reduce cost and resource wastage associated with patient noncompliance and early withdrawal. 
Download now!Technical / white paper

(b)(2) or not (b)(2)? That is the question. - Camargo

19-Aug-2013 - 505(b)(2) is more than a regulatory pathway - for many, it’s a unique strategy that can often result in product approval with lower risk, reduced development cost and faster speed to market. So, is (b)(2) for you? To find out...

Product Innovation